vs

Side-by-side financial comparison of Alexander & Baldwin, Inc. (ALEX) and Bioceres Crop Solutions Corp. (BIOX). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $51.0M, roughly 1.5× Alexander & Baldwin, Inc.). Alexander & Baldwin, Inc. runs the higher net margin — 7.4% vs -9.6%, a 17.0% gap on every dollar of revenue. On growth, Bioceres Crop Solutions Corp. posted the faster year-over-year revenue change (-16.8% vs -18.4%). Over the past eight quarters, Bioceres Crop Solutions Corp.'s revenue compounded faster (-8.4% CAGR vs -8.7%).

Alexander & Baldwin, Inc. is an American company that was once part of the Big Five companies in territorial Hawaii. The company currently operates businesses in real estate, land operations, and materials and construction. It was also the last "Big Five" company to cultivate sugarcane. As of 2020, it remains one of the State of Hawaii's largest private landowners, owning over 28,000 acres (11,000 ha) and operating 36 income properties in the state.

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

ALEX vs BIOX — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.5× larger
BIOX
$77.6M
$51.0M
ALEX
Growing faster (revenue YoY)
BIOX
BIOX
+1.5% gap
BIOX
-16.8%
-18.4%
ALEX
Higher net margin
ALEX
ALEX
17.0% more per $
ALEX
7.4%
-9.6%
BIOX
Faster 2-yr revenue CAGR
BIOX
BIOX
Annualised
BIOX
-8.4%
-8.7%
ALEX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ALEX
ALEX
BIOX
BIOX
Revenue
$51.0M
$77.6M
Net Profit
$3.8M
$-7.4M
Gross Margin
46.8%
Operating Margin
17.1%
9.3%
Net Margin
7.4%
-9.6%
Revenue YoY
-18.4%
-16.8%
Net Profit YoY
-69.7%
-20.2%
EPS (diluted)
$0.05
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALEX
ALEX
BIOX
BIOX
Q4 25
$51.0M
Q3 25
$50.2M
$77.6M
Q2 25
$51.7M
Q1 25
$53.7M
$60.6M
Q4 24
$62.4M
$98.8M
Q3 24
$61.9M
$93.3M
Q2 24
$51.0M
Q1 24
$61.2M
$84.0M
Net Profit
ALEX
ALEX
BIOX
BIOX
Q4 25
$3.8M
Q3 25
$14.3M
$-7.4M
Q2 25
$25.1M
Q1 25
$21.4M
$-1.6M
Q4 24
$12.4M
$605.2K
Q3 24
$19.0M
$-6.2M
Q2 24
$9.1M
Q1 24
$20.0M
$9.8M
Gross Margin
ALEX
ALEX
BIOX
BIOX
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
ALEX
ALEX
BIOX
BIOX
Q4 25
17.1%
Q3 25
38.2%
9.3%
Q2 25
54.4%
Q1 25
44.6%
1.5%
Q4 24
28.3%
14.5%
Q3 24
35.6%
2.5%
Q2 24
31.8%
Q1 24
38.9%
15.7%
Net Margin
ALEX
ALEX
BIOX
BIOX
Q4 25
7.4%
Q3 25
28.5%
-9.6%
Q2 25
48.6%
Q1 25
39.9%
-2.6%
Q4 24
19.9%
0.6%
Q3 24
30.7%
-6.6%
Q2 24
17.8%
Q1 24
32.6%
11.6%
EPS (diluted)
ALEX
ALEX
BIOX
BIOX
Q4 25
$0.05
Q3 25
$0.20
$-0.12
Q2 25
$0.35
Q1 25
$0.29
$-0.02
Q4 24
$0.16
$0.00
Q3 24
$0.26
$-0.10
Q2 24
$0.13
Q1 24
$0.28
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALEX
ALEX
BIOX
BIOX
Cash + ST InvestmentsLiquidity on hand
$11.3M
$15.5M
Total DebtLower is stronger
$491.6M
Stockholders' EquityBook value
$987.2M
$288.3M
Total Assets
$1.7B
$734.9M
Debt / EquityLower = less leverage
0.50×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALEX
ALEX
BIOX
BIOX
Q4 25
$11.3M
Q3 25
$17.3M
$15.5M
Q2 25
$8.6M
Q1 25
$16.9M
$38.5M
Q4 24
$33.4M
$29.2M
Q3 24
$17.9M
$32.3M
Q2 24
$29.5M
Q1 24
$15.7M
$16.4M
Total Debt
ALEX
ALEX
BIOX
BIOX
Q4 25
$491.6M
Q3 25
Q2 25
Q1 25
Q4 24
$474.8M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ALEX
ALEX
BIOX
BIOX
Q4 25
$987.2M
Q3 25
$1.0B
$288.3M
Q2 25
$1.0B
Q1 25
$1.0B
$345.0M
Q4 24
$1.0B
$346.3M
Q3 24
$998.2M
$346.0M
Q2 24
$1.0B
Q1 24
$1.0B
$348.5M
Total Assets
ALEX
ALEX
BIOX
BIOX
Q4 25
$1.7B
Q3 25
$1.7B
$734.9M
Q2 25
$1.6B
Q1 25
$1.6B
$798.2M
Q4 24
$1.7B
$835.2M
Q3 24
$1.7B
$827.3M
Q2 24
$1.6B
Q1 24
$1.6B
$836.1M
Debt / Equity
ALEX
ALEX
BIOX
BIOX
Q4 25
0.50×
Q3 25
Q2 25
Q1 25
Q4 24
0.47×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALEX
ALEX
BIOX
BIOX
Operating Cash FlowLast quarter
$79.5M
$14.4M
Free Cash FlowOCF − Capex
$27.3M
FCF MarginFCF / Revenue
53.5%
Capex IntensityCapex / Revenue
102.4%
Cash ConversionOCF / Net Profit
21.06×
TTM Free Cash FlowTrailing 4 quarters
$57.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALEX
ALEX
BIOX
BIOX
Q4 25
$79.5M
Q3 25
$24.5M
$14.4M
Q2 25
$16.5M
Q1 25
$26.0M
$23.3M
Q4 24
$98.0M
$-5.4M
Q3 24
$35.3M
$5.2M
Q2 24
$22.3M
Q1 24
$16.1M
$-17.4M
Free Cash Flow
ALEX
ALEX
BIOX
BIOX
Q4 25
$27.3M
Q3 25
$-3.7M
Q2 25
$11.8M
Q1 25
$21.8M
Q4 24
$77.0M
Q3 24
$31.4M
Q2 24
$18.0M
Q1 24
$12.3M
FCF Margin
ALEX
ALEX
BIOX
BIOX
Q4 25
53.5%
Q3 25
-7.4%
Q2 25
22.8%
Q1 25
40.6%
Q4 24
123.4%
Q3 24
50.8%
Q2 24
35.3%
Q1 24
20.1%
Capex Intensity
ALEX
ALEX
BIOX
BIOX
Q4 25
102.4%
Q3 25
56.1%
Q2 25
9.1%
Q1 25
7.8%
Q4 24
33.5%
Q3 24
6.2%
Q2 24
8.4%
Q1 24
6.1%
Cash Conversion
ALEX
ALEX
BIOX
BIOX
Q4 25
21.06×
Q3 25
1.71×
Q2 25
0.66×
Q1 25
1.21×
Q4 24
7.88×
-8.85×
Q3 24
1.86×
Q2 24
2.45×
Q1 24
0.80×
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons